Viyash Scientific Limited has secured regulatory clearance under Italian FDI 'Golden Power' regulations to acquire 100% of BioForLife Italia S.r.l. through its Irish subsidiary. The deal is now slated for completion within two months, by early November 2026, marking a key milestone in the company’s inorganic growth strategy.
Viyash Scientific Secures Regulatory Green Light for BioForLife Italia Acquisition
100% stake acquisition approved under Italian Golden Power regulations.
Transaction now expected to conclude by early November 2026.
Reader Takeaway: Italian regulatory clearance removes a key hurdle for Viyash; focus now shifts to final deal completion.
What just happened
Viyash Scientific Limited has announced that its step-down wholly-owned subsidiary, Alivira Animal Health Limited, Ireland, has successfully obtained the necessary regulatory approvals in Italy. The approval pertains to the acquisition of a 100% shareholding in Milan-based BioForLife Italia S.r.l. under the country's FDI (Golden Power) regulations.
Why this matters
The Italian 'Golden Power' framework is a stringent regulatory process designed to protect strategic assets. Receiving this clearance is a critical milestone that clears the path for the acquisition, removing a major procedural dependency that had previously kept the deal in a state of regulatory review.
Revised Timeline
Following the receipt of this clearance, Viyash Scientific has provided a revised timeline for the deal's closure. The transaction is now expected to be completed within two months from September 8, 2026. Aside from the updated completion date and the regulatory milestone, the material terms and conditions of the acquisition remain unchanged.
What to track next
Shareholders should monitor the company for the final closing announcement, which will signal the formal transfer of control and the integration of BioForLife Italia into the broader Alivira Animal Health portfolio.